# ScoreItem: Tempo de Protrombina (INR)

**ID:** `019bf31d-2ef0-708f-9735-029dd00e67b6`
**FullName:** Tempo de Protrombina (INR) (Exames - Laboratoriais)
**Unit:** ratio

**Preparation Metadata:**
- Quality Grade: **GOOD**
- Total Chunks: 30 de 10 artigos
- Avg Similarity: 0.550

---

## Contexto

Voc√™ √© um especialista em medicina funcional integrativa e est√° contribuindo com o **Escore Plenya** ‚Äî um escore completo de an√°lise de sa√∫de que avalia todos os aspectos da sa√∫de, performance e longevidade humana. Cada ScoreItem representa um par√¢metro cl√≠nico, laboratorial, gen√©tico, comportamental ou hist√≥rico que comp√µe esse escore.

Seu papel √© gerar conte√∫do cl√≠nico de alta qualidade para enriquecer cada par√¢metro do escore com relev√¢ncia cl√≠nica, orienta√ß√£o ao paciente e conduta pr√°tica.

**Regras inegoci√°veis:**
- Use **apenas** o conhecimento m√©dico real consolidado e os dados presentes nos chunks cient√≠ficos abaixo
- **N√£o alucine, n√£o invente** dados, estudos, estat√≠sticas ou refer√™ncias que n√£o estejam nos chunks ou no seu conhecimento m√©dico estabelecido
- Se um dado espec√≠fico n√£o constar nos chunks e n√£o for do seu conhecimento consolidado, **n√£o o inclua**
- Seja preciso: prefira omitir a inventar

## Instru√ß√£o

Com base nos chunks cient√≠ficos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `019bf31d-2ef0-708f-9735-029dd00e67b6`.**

```json
{
  "score_item_id": "019bf31d-2ef0-708f-9735-029dd00e67b6",
  "clinical_relevance": "Texto t√©cnico para m√©dicos (1000-5000 chars): defini√ß√£o fisiol√≥gica precisa, valores de refer√™ncia e interpreta√ß√£o, fisiopatologia resumida, dados epidemiol√≥gicos com n√∫meros concretos, estratifica√ß√£o de risco baseada em evid√™ncias.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que √© este par√¢metro sem jarg√µes, por que √© importante para a sa√∫de, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta cl√≠nica em Markdown (1000-5000 chars): investiga√ß√£o complementar necess√°ria, crit√©rios de encaminhamento a especialistas, interven√ß√µes baseadas em evid√™ncias. Use bullet points, se√ß√µes e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto cl√≠nico: 1-9 pts
- Alto impacto cl√≠nico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Crit√©rios: gravidade/mortalidade (40%), preval√™ncia (30%), intervencionabilidade (30%)

---

### Contexto Cient√≠fico

**ScoreItem:** Tempo de Protrombina (INR) (Exames - Laboratoriais)
**Unidade:** ratio

**30 chunks de 10 artigos (avg similarity: 0.550)**

### Chunk 1/30
**Article:** International Normalized Ratio: Assessment, Monitoring, and Clinical Implications (2025)
**Journal:** StatPearls
**Section:** abstract | **Similarity:** 0.696

Comprehensive review on INR monitoring for anticoagulation therapy, covering assessment methods, therapeutic ranges, and clinical implications. Updated February 2025 with current guidelines for warfarin management and monitoring protocols.

---

### Chunk 2/30
**Article:** Utility of TTR-INR guided warfarin adjustment protocol to improve time in therapeutic range in patients with atrial fibrillation receiving warfarin (2024)
**Journal:** Scientific Reports
**Section:** abstract | **Similarity:** 0.655

Prospective cohort study demonstrating that TTR-INR guided warfarin adjustment protocol significantly improves time in therapeutic range from 65% to 80% in atrial fibrillation patients. Proportion of patients achieving adequate anticoagulation control increased from 47% to 88% over 12 months.

---

### Chunk 3/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.602

stroke,and
CHADS2score.Therewasasuggestionthatmajorbleedingwassignicantlyreducedinpeopleattendingcenterswheretimeintherapeuticinternationalnormalizedratio(INR)range
was<66%comparedwithcenterswith$66%timeinrange(interactionP¬º0.02).ThissuggeststhatbenetsofNOACsareinpartaresultoftheirsimplerpharmacokineticproleanddosing.714The2021meta-analysisthatfocusedonCKDsubgroupsfrom7trialsfoundthatbleedingeventswerealso
notsignicantlydifferentamongthoseallocatedNOACsversuswarfarin(HR:0.83;95%CI:0.58‚Äì1.18).715DatainCKDG5ondialysiswerelimitedtoobservationalstudies.715Ourevidencereviewwasagainlimitedtoasmallnumberofstudiesreportingsubtypesofbleedingoutcomes,andsoanalysesfoundimpreciseestimatesoftreatmenteffect.The
ndingswerequalitativelyconsistentwiththetotalityoftheevidence(Figure42,SupplementaryTableS15716‚Äì722).ThereviewraisedahypothesisthatsomeNOACsmaybemore
likelytoreducetheriskofbleeding.However,giventhe
evidenceofeffectmodicationbytimeintherapeuticrangeinthewarfaringroup,wehavenotprovi

---

### Chunk 4/30
**Article:** Outcomes of Warfarin Home INR Monitoring vs Office-Based Monitoring: a Retrospective Claims-Based Analysis (2024)
**Journal:** Journal of General Internal Medicine
**Section:** abstract | **Similarity:** 0.592

Retrospective claims-based analysis comparing patient self-testing (PST) versus laboratory-based INR monitoring. Demonstrates real-world outcomes and effectiveness of home INR monitoring technologies for warfarin management, with implications for time in therapeutic range and patient safety.

---

### Chunk 5/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.588

04 (0.07, 16.70)0.51 (0.24, 1.09)CrCl 30‚Äì50CrCl 30‚Äì4946 countries
45 countries2.8 yrs
707 dysEdoxaban 60 mg
Rivaroxaban 20 mgWarfarin
Warfarin0.46 (0.26, 0.82)
0.82 (0.41, 1.60)0.60 (0.34, 1.05)Author, yearAll clinically relevant bleeding‚Ä†Hijazi, 2021Stanifer, 2020Hori, 2013Fox, 2011Subtotal (I2 = 79.9%, P=0.002)Fatal bleedingBohula, 2016Hori, 2013Subtotal (I2 = 0.0%, P=0.595)Major bleeding‚Ä†Hijazi, 2021Stanifer, 2020Hijazi, 2018Bohula, 2016Hori, 2013Fox, 2011Subtotal (I2 = 79.0%, P=0.000)Intracranial hemorrhageBohula, 2016Fox, 2011Subtotal (I2 = 38.2%, P=0.203)Hori, 2013Fox, 2011Subtotal (I2 = 14.1%, P=0.281)CrCl 30‚Äì49CrCl 30‚Äì49Japan
45 countries2.5 yrs
707 dysRivaroxaban 10 mg
Rivaroxaban 20 mgWarfarin
Warfarin1.35 (0.82, 2.22)
1.01 (0.85, 1.20)1.06 (0.86, 1.31)Clinically relevant nonmajor bleeding‚Ä°Weighted hazard ratio of bleeding0.20.5512Favors NOACFavors control
Figure42|Pooledhazardratio(HR)comparingnon‚ÄìvitaminKantagonistoralanticoagulants(NOACs)withwarfarinamongpe

---

### Chunk 6/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.569

International(2024)105(Suppl4S),S117‚ÄìS314S241

Harms.The2014meta-analysisof4largephaseIIItrialsfoundthatNOACsreducedtheriskofdeathfromanycauseby10%,conrmingnetsafety(RR:0.90;95%CI:0.85‚Äì0.95).Comparedwithwarfarin,NOACsreducedtheriskofintracranialhemorrhage(denedashemorrhagicstroke,epidural,subdural,andsubarachnoidhemorrhage)
byaboutone-half(RR:0.48;95%CI:0.39‚Äì0.59),andtheriskofgastrointestinalbleedingwasincreasedbyabout
one-quarter(RR:1.25;95%CI:1.01‚Äì1.55).Overall,therewasnocleareffectonthecombinationofthese2safety
outcomesreferredtoasmajorbleeding(RR:0.86;95%CI:
0.73‚Äì1.00).714TherewerelargeamountsofdataonmajorbleedinginthosewithaCrClof<50ml/min,soreassuringsafetydataclearlyextendedtopeoplewith
CKD.Therewerealsoconsistentsafetydatainsubgroup
analysesbyage,sex,priordiabetes,priorstroke,and
CHADS2score.Therewasasuggestionthatmajorbleedingwassignicantlyreducedinpeopleattendingcenterswheretimeintherapeuticinternationalnormalizedratio(INR)range
was<66%comparedwithcenterswith$66%

---

### Chunk 7/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.565

llationandadvancedchronickidneydisease.Circulation.2020;141:1384‚Äì1392.722.HijaziZ,AlexanderJH,LiZ,etal.ApixabanorvitaminKantagonistsandaspirinorplaceboaccordingtokidneyfunctioninpatientswithatrialbrillationafteracutecoronarysyndromeorpercutaneouscoronaryinterventioninsightsfromtheAUGUSTUStrial.Circulation.2021;143:1215‚Äì1223.723.AltawalbehSM,AlshogranOY,SmithKJ.Cost-utilityanalysisofapixaban
versuswarfarininatrialbrillationpatientswithchronickidneydisease.ValueHealth.2018;21:1365‚Äì1372.724.HeidbuchelH,VerhammeP,AlingsM,etal.UpdatedEuropeanHeart
RhythmAssociationpracticalguideontheuseofnon-vitamin-K
antagonistanticoagulantsinpatientswithnon-valvularatrial
brillation:executivesummary.EurHeartJ.2017;38:2137‚Äì2149.725.VondracekSF,TeitelbaumI,KiserTH.Principlesofkidney
pharmacotherapyforthenephrologist:CoreCurriculum2021.AmJKidneyDis.2021;78:442‚Äì458.726.DorksM,AllersK,SchmiemannG,etal.Inappropriatemedicationinnon-
hospitalizedpatientswithrenalinsufciency:asystematicreview.JAmGeri

---

### Chunk 8/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.560

0 ml/min‚â•24 h‚â•48 h‚â•24 h‚â•48 hCrCl 50‚Äì80 ml/min‚â•36 h‚â•72 h‚â•24 h‚â•48 hCrCl 30‚Äì50 ml/mina‚â•48 h‚â•96 h‚â•24 h‚â•48 hCrCl 15‚Äì30 ml/minaNo ocial indicationNo ocial indication‚â•36 h‚â•48 hCrCl <15 ml/minNo ocial indication for useThere is no need for bridging with LMWH/UFH
Figure44|Adviceonwhentodiscontinuenon‚ÄìvitaminKantagonistoralanticoagulants(NOACs)beforeprocedures(lowvs.highrisk).Theboldvaluesdeviatefromthecommonstoppingruleof$24-hourlowrisk,$48-hourhighrisk.Lowriskisdenedasalowfrequencyofbleedingand/orminorimpactofableed.Highriskisdenedasahighfrequencyofbleedingand/orimportantclinicalimpact.AdaptedfromHeidbuchelH,VerhammeP,AlingsM,etal.UpdatedEuropeanHeartRhythmAssociationpracticalguideontheuseofnon‚Äìvitamin-Kantagonistanticoagulantsinpatientswithnon-valvularatrialbrillation:executivesummary.EurHeartJ.2017;38:2137‚Äì2149.724aManyofthesepeoplemaybeonlowerdoseofdabigatran(110mgtwiceperday[b.i.d.])orapixaban(2.5mgb.i.d.),orhavetobeonthelowerdoseofrivaroxaban(

---

### Chunk 9/30
**Article:** Bases Metab√≥licas das Doen√ßas Cr√¥nicas e Gerenciamento - Inflama√ß√£o 2 (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.559

ejo da inflama√ß√£o.
**A suplementa√ß√£o com curcuminoides, padronizada a 95%, √© uma estrat√©gia anti-inflamat√≥ria eficaz, com doses que variam de 500 mg a 2g, mas que exigem cautela em pacientes que usam anticoagulantes.**
- Uma meta-an√°lise de 15 ensaios cl√≠nicos randomizados valida o estudo dos efeitos da curcumina.
- A dose inicial recomendada √© de 500 mg, podendo chegar a um m√°ximo de 2g por dia.
- Para pacientes que usam anticoagulantes, a dose m√°xima recomendada √© de 500 mg, com uma dose de seguran√ßa sugerida de 250 mg (preferencialmente lipossomada para melhor absor√ß√£o).
- A absor√ß√£o √© frequentemente melhorada pela adi√ß√£o de 10 mg de piperina, que pode, no entanto, causar rea√ß√µes al√©rgicas em algumas pessoas.

---

### Chunk 10/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.559

Theyofferbenetsintermsofeaseofmonitoring.CKDdoesnotappeartoimportantlymodifythesebenets,atleastdowntoG4.PracticePoint3.16.2:NOACdoseadjustmentforGFRisrequired,withcautionneededatCKDG4‚ÄìG5.DosesofNOACsmayneedtobemodiedinpeoplewithdecreasedGFRtakingintoconsiderationtheage,weight,andGFRofapersonwithCKD(Figure43710).Consulttherelevantsummariesofproductcharacteristicsforthelatest
informationondosing(Chapter4).PracticePoint3.16.3:DurationofNOACdiscontinuationbeforeelectiveproceduresneedstoconsiderproceduralbleedingrisk,NOACprescribed,andlevelofGFR(Figure44).710,724
eCrCl (ml/min)aWarfarinApixabanbDabigatranEdoxabancRivaroxaban>95Adjusted dose (INR 2‚Äì3)5 mg b.i.d.150 mg b.i.d.60 mg QDd20 mg QD51‚Äì95Adjusted dose (INR 2‚Äì3)5 mg b.i.d.150 mg b.i.d.60 mg QD20 mg QD31‚Äì50Adjusted dose (INR 2‚Äì3)5 mg b.i.d.
150 mg b.i.d.

---

### Chunk 11/30
**Article:** 2025 Guidelines for direct oral anticoagulants: a practical guidance on the prescription, laboratory testing, peri-operative and bleeding management (2025)
**Journal:** Internal Medicine Journal
**Section:** abstract | **Similarity:** 0.555

Updated guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) comparing direct oral anticoagulants (DOACs) with warfarin/VKAs. Addresses advantages of DOACs including predictable effect, no routine monitoring requirement, and comparison with INR-based warfarin management.

---

### Chunk 12/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** conclusion | **Similarity:** 0.546

R.eIncountrieswhere110mgb.i.d.isapproved,healthcareprovidersmaypreferthisdoseafterclinicalassessmentofthromboembolicversusbleedingrisk.ThisdosehasnotbeenapprovedforusebytheUSFDA.fNOACdoseslistedinparenthesisaredosesthatdonotcurrentlyhaveanyclinicalorefcacydata.ThedosesofNOACsapixaban5mgb.i.d.,brivaroxaban15mgeveryday,anddabigatran75mgb.i.d.areincludedintheUSFDA‚Äìapprovedlabelingbasedonlimiteddosepharmacokineticandpharmacodynamicsdatawithnoclinicalsafetydata.Wesuggestconsiderationofthelowerdoseofapixaban2.5mgoralb.i.d.inCKDG5andG5Dtoreducebleedingriskuntilclinicalsafetydataareavailable.gDabigatran75mgavailableonlyintheUnitedStates.hThedosewashalvedifanyofthefollowing:estimatedCrClof30‚Äì50ml/min,bodyweightof#60kg,orconcomitantuseofverapamilorquinidine(potentP-glycoproteininhibitors).INR,internationalnormalizedratio;QD,everyday.ReproducedfromTurakhiaMP,BlankestijnPJ,CarreroJJ,etal.Chronickidneydiseaseandarrhythmias:conclusionsfromaKidneyDisease:
ImprovingGlobalOutcomes(KDIGO)Controvers

---

### Chunk 13/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.544

entlevelsofrisk(basedonageandsex)S240Figure39.Meta-analyzedadjustedprevalenceofatrialbrillationfromcohortscontributingtotheChronicKidneyDiseasePrognosisConsortium,bydiabetesstatusS241Figure40.StrategiesforthediagnosisandmanagementofatrialbrillationS242Figure41.Pooledhazardratio(HR)comparingnon‚ÄìvitaminKantagonistoralanticoagulants(NOACs)withwarfarinamongpeoplewithchronickidneydiseaseintermsofstrokeS243Figure42.Pooledhazardratio(HR)comparingnon‚ÄìvitaminKantagonistoralanticoagulants(NOACs)withwarfarinamongpeoplewithchronickidneydiseaseintermsofbleedingS244Figure43.Evidencefrom(a)randomizedcontrolledtrials(RCTs)regardingtherapeuticanticoagulationdosebyglomerularltrationrate(GFR)and(b)inareaswhereRCTsarelackingS245Figure44.Adviceonwhentodiscontinuenon‚ÄìvitaminKantagonistoralanticoagulants(NOACs)beforeprocedures(lowvs.highrisk)
www.kidney-international.orgcontentsKidneyInternational(2024)105(Suppl4S),S117‚ÄìS314S121

S248Figure45.Selectedherbalremediesanddietarysupplementswithevidence

---

### Chunk 14/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.542

beassociatedwithhighercostsandachievefewerquality-adjustedlife-yearscomparedwithNOACs.723Considerationsforimplementation.Adecisionnottoanti-coagulateforthromboembolicprophylaxisduetolowrisk
wouldideallybere-evaluatedateachconsultationandatleast
every6months.WhenusingantithrombotictherapyinpeoplewithCKD,itisprudenttotreatmodiableriskfactorsforbleeding(e.g.,alcoholintake)andusegastroprophylaxiswithaPPI,particularlywhencombinedwithantiplatelet
therapy.RationaleAnumberoflargeRCTsdemonstratedthatNOACsreduce
theriskofintracranialbleedingcomparedwithwarfarinand,
overall,modestlyreducemortalityinpeoplewithatrial
KidneyfunctionCountryFollow-up
lengthIntervention*ControlHR (95% CI)CrCl 30‚Äì50eGFR 25‚Äì50eGFR <50CrCl 30‚Äì50CrCl 30‚Äì49CrCl 30‚Äì4933 countries39 countries44 countries46 countriesJapan45 countries6 mos1.8 yrs1.8 yrs2.8 yrs2.5 yrs707 dysApixaban 2.5‚Äì5 mgApixaban 2.5‚Äì5 mgDabigatran 150 mgEdoxaban 60 mgRivaroxaban 10 mgRivaroxaban 20 mgWarfarinWarfarinWarfarinWarfarinWarfarinWar

---

### Chunk 15/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.540

P=0.980)Ischemic strokeStanifer, 2020Hijazi, 2018Bohula, 2016Hori, 2013Fox, 2011
Subtotal (I2=19.5%, P=0.291)Hemorrhagic strokeBohula, 2016Hori, 2013Fox, 2011Subtotal (I2=0.0%, P=0.619)Weighted hazard ratio of stroke0.20.5512Favors NOACFavors control
Figure41|Pooledhazardratio(HR)comparingnon‚ÄìvitaminKantagonistoralanticoagulants(NOACs)withwarfarinamongpeoplewithchronickidneydiseaseintermsofstroke.BohulaE,GiuglianoR,RuffC,etal.ImpactofrenalfunctiononoutcomeswithedoxabanintheENGAGEAF-TIMI48trial.Circulation.2016;134:24‚Äì36716;FoxKA,PicciniJP,WojdylaD,etal.Preventionofstrokeandsystemicembolismwithrivaroxabancomparedwithwarfarininpatientswithnon-valvularatrialbrillationandmoderaterenalimpairment.EurHeartJ.2011;32:2387‚Äì2394718;HijaziZ,HohnloserSH,OldgrenJ,etal.Efcacyandsafetyofdabigatrancomparedwithwarfarininpatientswithatrialbrillationinrelationtorenalfunctionovertime‚ÄîaRE-LYtrialanalysis.AmHeartJ.2018;198:169‚Äì177719;HijaziZ,AlexanderJH,LiZ,etal.ApixabanorvitaminKantagonistsand

---

### Chunk 16/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.540

vant nonmajor bleeding‚Ä°Weighted hazard ratio of bleeding0.20.5512Favors NOACFavors control
Figure42|Pooledhazardratio(HR)comparingnon‚ÄìvitaminKantagonistoralanticoagulants(NOACs)withwarfarinamongpeoplewithchronickidneydiseaseintermsofbleeding.BohulaE,GiuglianoR,RuffC,etal.ImpactofrenalfunctiononoutcomeswithedoxabanintheENGAGEAF-TIMI48trial.Circulation.2016;134:24‚Äì36716;FoxKA,PicciniJP,WojdylaD,etal.Preventionofstrokeandsystemicembolismwithrivaroxabancomparedwithwarfarininpatientswithnon-valvularatrialbrillationandmoderaterenalimpairment.EurHeartJ.2011;32:2387‚Äì2394718;HijaziZ,HohnloserSH,OldgrenJ,etal.Efcacyandsafetyofdabigatrancomparedwithwarfarininpatientswithatrialbrillationinrelationtorenalfunctionovertime‚ÄîaRE-LYtrialanalysis.AmHeartJ.2018;198:169‚Äì177719;HoriM,MatsumotoM,TanahashiN,etal.SafetyandefcacyofadjusteddoseofrivaroxabaninJapanesepatientswithnon-valvularatrialbrillation:subanalysisofJ-ROCKETAFforpatientswithmoderaterenalimpairment.CircJ.2013;77:632‚Äì638720;S

---

### Chunk 17/30
**Article:** Abordagem Funcional Integrativa Aplicada a Cada √Årea - Parte XIII (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.538

co da dislipidemia.
- [ ] 2. Analisar criticamente os estudos sobre o Inclisiran (Cibrava), focando na diferen√ßa entre desfechos substitutos (redu√ß√£o de LDL) e desfechos cl√≠nicos duros (mortalidade, infarto, AVC).
- [ ] 3. Utilizar o site `the-nnt.com` para pesquisar o NNT e NNH de outros medicamentos prescritos na pr√°tica cl√≠nica.
- [ ] 4. Refletir sobre a influ√™ncia da ind√∫stria farmac√™utica e dos interesses financeiros na prescri√ß√£o de novos medicamentos.
- [ ] 5. Estudar a diferen√ßa entre risco relativo e risco absoluto para interpretar criticamente os achados de estudos cient√≠ficos.
- [ ] 6. Pesquisar sobre os diferentes tipos de √¥mega-3 (EPA, DHA, ALA) e suas formula√ß√µes para entender como a qualidade do suplemento afeta os resultados.
- [ ] 7. Investigar os exames de subfracionamento de LDL e a rela√ß√£o ApoA/ApoB como ferramentas de avalia√ß√£o de risco cardiovascular mais precisas que o LDL total.
- [ ] 8.

---

### Chunk 18/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.537

an45 countries6 mos1.8 yrs1.8 yrs2.8 yrs2.5 yrs707 dysApixaban 2.5‚Äì5 mgApixaban 2.5‚Äì5 mgDabigatran 150 mgEdoxaban 60 mgRivaroxaban 10 mgRivaroxaban 20 mgWarfarinWarfarinWarfarinWarfarinWarfarinWarfarin0.51 (0.28, 0.93)0.59 (0.45, 0.77)1.11 (0.87, 1.14)0.76 (0.58, 0.98)0.89 (0.36, 2.18)0.98 (0.73, 1.30)
0.80 (0.61, 1.05)NOTE: Weights are from random eects analysisCrCl 30‚Äì50eGFR 25‚Äì50CrCl 30‚Äì49CrCl 30‚Äì4933 countries39 countriesJapan45 countries6 mos1.8 yrs2.5 yrs707 dysApixaban 2.5‚Äì5 mgApixaban 2.5‚Äì5 mgRivaroxaban 10 mgRivaroxaban 20 mgWarfarinWarfarinWarfarinWarfarin0.59 (0.41, 0.84)0.35 (0.17, 0.72)1.22 (0.78, 1.91)0.98 (0.85, 1.15)0.76 (0.51, 1.14)CrCl 30‚Äì50CrCl 30‚Äì4946 countries
Japan2.8 yrs
2.5 yrsEdoxaban 60 mg
Rivaroxaban 10 mgWarfarin
Warfarin0.48 (0.22, 1.07)
1.04 (0.07, 16.70)0.51 (0.24, 1.09)CrCl 30‚Äì50CrCl 30‚Äì4946 countries
45 countries2.8 yrs
707 dysEdoxaban 60 mg
Rivaroxaban 20 mgWarfarin
Warfarin0.46 (0.26, 0.82)
0.82 (0.41, 1.60)0.60 (0.34, 1.05)Au

---

### Chunk 19/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.537

sfor
ischaemicstrokeinatrialbrillationacrossthespectrumofkidneyfunction.EurHeartJ.2021;42:1476‚Äì1485.714.RuffCT,GiuglianoRP,BraunwaldE,etal.Comparisonoftheefcacyandsafetyofneworalanticoagulantswithwarfarininpatientswithatrial
brillation:ameta-analysisofrandomisedtrials.Lancet.2014;383:955‚Äì962.715.SuX,YanB,WangL,etal.Oralanticoagulantagentsinpatientswith
atrialbrillationandCKD:asystematicreviewandpairwisenetworkmeta-analysis.AmJKidneyDis.2021;78:678‚Äì689.e1.716.BohulaE,GiuglianoR,RuffC,etal.Impactofrenalfunctiononoutcomes
withedoxabanintheENGAGEAF-TIMI48trial.Circulation.2016;134:24‚Äì36.717.ChashkinaMI,AndreevDA,KozlovskayaNL,etal.[Safetyperformanceof
rivaroxabanversuswarfarininpatientswithatrialbrillationand
www.kidney-international.orgreferencesKidneyInternational(2024)105(Suppl4S),S117‚ÄìS314S309

advancedchronickidneydisease].Kardiologiia.2020;60:1322[inRussian].718.FoxKA,PicciniJP,WojdylaD,etal.Preventionofstrokeandsystemicembolismwithrivaroxabancomparedwithwarfarininpati

---

### Chunk 20/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.536

tematicreviewandmeta-analysis.EurJPrevCardiol.2022;28:1953‚Äì1960.926.KimachiM,FurukawaTA,KimachiK,etal.Directoralanticoagulants
versuswarfarinforpreventingstrokeandsystemicembolicevents
amongatrialbrillationpatientswithchronickidneydisease.CochraneDatabaseSystRev.2017;11:CD011373.927.SterneJAC,SavovicJ,PageMJ,etal.RoB2:arevisedtoolforassessingriskofbiasinrandomisedtrials.BMJ.2019;366:l4898.928.WhitingPF,RutjesAW,WestwoodME,etal.QUADAS-2:arevisedtoolfor
thequalityassessmentofdiagnosticaccuracystudies.AnnInternMed.2011;155:529‚Äì536.929.WhitingP,SavovicJ,HigginsJP,etal.ROBIS:anewtooltoassessriskofbiasinsystematicreviewswasdeveloped.JClinEpidemiol.2016;69:225‚Äì234.930.DerSimonianR,LairdN.Meta-analysisinclinicaltrials.ControlClinTrials.1986;7:177‚Äì188.931.FreemanMF,TukeyJ.Transformationsrelatedtotheangularandthe
squareroot.AnnMathStat.1950;21:601‚Äì611.932.NewcombeRG.Two-sidedcondenceintervalsforthesingleproportion:comparisonofsevenmethods.StatMed.1998;17:857‚Äì872.933.HigginsJP,Tho

---

### Chunk 21/30
**Article:** Suplementa√ß√£o I (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.524

rar intera√ß√µes com anticoagulantes cumar√≠nicos; detalhamento em cardiologia futura.
## Orienta√ß√µes Pr√°ticas e Ferramentas Sugeridas
- Mapas e fluxogramas: objetivos da aula; decis√£o de via (sabor/estabilidade/rapidez); quando considerar K2 com D; checklist de qualidade de suplementos (laudos, certifica√ß√µes, fornecedores, pre√ßo, biodisponibilidade).
- Visuals: imagens de cromossomos/tel√¥meros; gr√°ficos de biomarcadores (PCR/IL-6) em resveratrol; comparativos ‚Äúmanipulado confi√°vel vs produto pronto‚Äù; mapas bioqu√≠micos de amino√°cidos ‚Üí neurotransmissores.
- Comunica√ß√£o √©tica: frases-modelo para recusar infus√µes sem indica√ß√£o; foco em necessidade cl√≠nica e transpar√™ncia de custo-benef√≠cio.
## Perguntas dos Alunos
Nenhuma pergunta foi levantada pelos alunos.

---

## Concept Insights

N√£o foram identificados conceitos novos

---

### Chunk 22/30
**Article:** Re-evaluation of Hematocrit as a Determinant of Thrombotic Risk in Erythrocytosis (2019)
**Journal:** Haematologica
**Section:** abstract | **Similarity:** 0.521

An√°lise cr√≠tica do hemat√≥crito como fator de risco tromb√≥tico, revisando evid√™ncias sobre o limiar terap√™utico de 45% e outros fatores de risco associados.

---

### Chunk 23/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.519

ngaCKDparametertothe
CHA2DS2-VAScscore,whichalreadyincludestheseparameters,wouldbeexpectedtohavelittleeffect.Thereis
considerablescopetoimprovethepredictiveperformance
ofthromboprophylaxisriskscoresforuseinCKD.713Recommendation3.16.1:Werecommenduseofnon‚ÄìvitaminKantagonistoralanticoagulants(NOACs)inpreferencetovitaminKantagonists(e.g.,
warfarin)forthromboprophylaxisinatrialbrilla-tioninpeoplewithCKDG1‚ÄìG4(1C).ThisrecommendationputshighvalueontheuseofNOACs,alsoreferredtoasdirect-actingoralanticoagulantsorDOACs,inpeoplewithCKDduetotheirsimplerpharmacokineticprole,dosing,andmonitoringthanvitaminKantagonistsandduetotheirimprovedefcacyandrelativelysimilarsafetyprole.AlthoughpeoplewithCKDG4‚ÄìG5havebeenunderstudiedinRCTs,implementationinsuchgroupscanbeachievedafter
consideringchoiceofNOACanddosing.KeyinformationBalanceofbenetsandharms.Benets.Datafrom42,411participantswhoreceivedNOACsand29,272participants
whoreceivedwarfarinin4phaseIIItrialsweremeta-analyzed
in2014.Suchtrialslargelyex

---

### Chunk 24/30
**Article:** Confounders in Identification and Analysis of Inflammatory Biomarkers in Cardiovascular Diseases (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.517

atherosclerosis:Resultsfromaprospective,parallel-groupcohortstudy.Clin.Chim.Acta2015,447,16‚Äì22.[CrossRef]101.Hijazi,Z.;Lindahl,B.;Oldgren,J.;Andersson,U.;Lindb√§ck,J.;Granger,C.B.;Alexander,J.H.;Gersh,B.J.;Hanna,M.;Harjola,V.;etal.RepeatedMeasurementsofCardiacBiomarkersinAtrialFibrillationandValidationoftheABCStrokeScoreOverTime.J.Am.HeartAssoc.2017,6,e004851.[CrossRef]102.Abramson,J.L.;Lewis,C.;Murrah,N.V.;Anderson,G.T.;Vaccarino,V.RelationofC-ReactiveProteinandTumorNecrosisFactor-AlphatoAmbulatoryBloodPressureVariabilityinHealthyAdults.Am.J.Cardiol.2006,98,649‚Äì652.[CrossRef]103.Simundic,A.-M.;Kackov,S.;Miler,M.;Fraser,C.G.;Petersen,P.H.TermsandSymbolsUsedinStudiesonBiologicalVariation:TheNeedforHarmonization.Clin.Chem.2015,61,438‚Äì439.[CrossRef]
	
	
Getulio Jos√© Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

Biomolecules2021,11,1464
17of17
104.Khuseyinova,N.;Greven,S.;R√ºckerl,R.;Trischler,G.;Loewel,H.;Peters,A.;

---

### Chunk 25/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.514

thCKDwithacuteorunstablecoronarydisease,unacceptablelevelsofangina(e.g.,patientdissatisfaction),leftventricularsystolicdysfunctionattributabletoischemia,orleftmaindisease.
summaryofrecommendationstatementsandpracticepointswww.kidney-international.orgS162KidneyInternational(2024)105(Suppl4S),S117‚ÄìS314

3.16CKDandatrialbrillationPracticePoint3.16.1:Followestablishedstrategiesforthediagnosisandmanagementofatrialbrillation(Figure40).Recommendation3.16.1:Werecommenduseofnon‚ÄìvitaminKantagonistoralanticoagulants(NOACs)inpreferencetovitaminKantagonists(e.g.,warfarin)forthromboprophylaxisinatrialbrillationinpeoplewithCKDG1‚ÄìG4(1C).PracticePoint3.16.2:NOACdoseadjustmentforGFRisrequired,withcautionneededatCKDG4‚ÄìG5.PracticePoint3.16.3:DurationofNOACdiscontinuationbeforeelectiveproceduresneedstoconsiderproceduralbleedingrisk,NOACprescribed,andlevelofGFR(Figure44).

---

### Chunk 26/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.511

ncomparedwithwarfarininpatientswithatrialbrillationinrelationtorenalfunctionovertime‚ÄîaRE-LYtrialanalysis.AmHeartJ.2018;198:169‚Äì177719;HijaziZ,AlexanderJH,LiZ,etal.ApixabanorvitaminKantagonistsandaspirinorplaceboaccordingtokidneyfunctioninpatientswithatrialbrillationafteracutecoronarysyndromeorpercutaneouscoronaryintervention:insightsfromtheAUGUSTUStrial.Circulation.2021;143:1215‚Äì1223722;HoriM,MatsumotoM,TanahashiN,etal.SafetyandefcacyofadjusteddoseofrivaroxabaninJapanesepatientswithnon-valvularatrialbrillation:subanalysisofJ-ROCKETAFforpatientswithmoderaterenalimpairment.CircJ.2013;77:632‚Äì638720;StaniferJ,PokorneyS,ChertowG,etal.Apixabanversuswarfarininpatientswithatrialbrillationandadvancedchronickidneydisease.Circulation.2020;141:1384‚Äì1392.721CI,condenceinterval;CrCl,creatinineclearance;eGFR,estimatedglomerularltrationrate.

---

### Chunk 27/30
**Article:** Confounders in Identification and Analysis of Inflammatory Biomarkers in Cardiovascular Diseases (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.509

lresearch.Curr.Opin.Clin.Nutr.Metab.Care2010,13,541‚Äì547.[CrossRef]92.Levi,M.;VanDerPoll,T.InÔ¨Çammationandcoagulation.Crit.CareMed.2010,38,S26‚ÄìS34.[CrossRef]93.Cemin,R.;Daves,M.Pre-analyticvariabilityincardiovascularbiomarkertesting.J.Thorac.Dis.2015,7,E395‚ÄìE401.[CrossRef][PubMed]94.Rodr√≠guez,A.D.;Gonz√°lez,P.A.DiurnalVariationsinBiomarkersUsedinCardiovascularMedicine:ClinicalSigniÔ¨Åcance.Rev.Esp.Cardiol.2009,62,1340‚Äì1341.[CrossRef]95.Rudnicka,A.R.;Rumley,A.;Lowe,G.D.;Strachan,D.P.Diurnal,Seasonal,andBlood-ProcessingPatternsinLevelsofCirculatingFibrinogen,FibrinD-Dimer,C-ReactiveProtein,TissuePlasminogenActivator,andvonWillebrandFactorina45-Year-OldPopulation.Circulation2007,115,996‚Äì1003.[CrossRef][PubMed]96.Dominguez-Rodriguez,A.;Tome,M.C.-P.;Abreu-Gonzalez,P.InterrelationbetweenarterialinÔ¨Çammationinacutecoronarysyndromeandcircadianvariation.WorldJ.Cardiol.2011,3,57‚Äì58.[CrossRef]97.Tirumalai,R.S.;Chan,K.C.;Prieto,D.A.;Issaq,H.J.;Conrads,T.P.;Veenstra,T.D.Characterizati

---

### Chunk 28/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** conclusion | **Similarity:** 0.506

highrisk.Lowriskisdenedasalowfrequencyofbleedingand/orminorimpactofableed.Highriskisdenedasahighfrequencyofbleedingand/orimportantclinicalimpact.AdaptedfromHeidbuchelH,VerhammeP,AlingsM,etal.UpdatedEuropeanHeartRhythmAssociationpracticalguideontheuseofnon‚Äìvitamin-Kantagonistanticoagulantsinpatientswithnon-valvularatrialbrillation:executivesummary.EurHeartJ.2017;38:2137‚Äì2149.724aManyofthesepeoplemaybeonlowerdoseofdabigatran(110mgtwiceperday[b.i.d.])orapixaban(2.5mgb.i.d.),orhavetobeonthelowerdoseofrivaroxaban(15mgQD)oredoxaban(30mgQD).Dabigatran110mgb.i.d.hasnotbeenapprovedforusebytheUSFoodandDrug
Administration.CrCl,creatinineclearance,LMWH,low-molecular-weightheparin;UFH,unfractionatedheparin.ReproducedfromTurakhiaMP,
BlankestijnPJ,CarreroJJ,etal.Chronickidneydiseaseandarrhythmias:conclusionsfromaKidneyDisease:ImprovingGlobalOutcomes
(KDIGO)ControversiesConference.EurHeartJ.2018;39:2314‚Äì2325.710¬™TheAuthor(s)2018.PublishedbyOxfordUniversityPressonbehalfoftheEuropeanSocietyofC

---

### Chunk 29/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.505

4S),S117‚ÄìS314S309

advancedchronickidneydisease].Kardiologiia.2020;60:1322[inRussian].718.FoxKA,PicciniJP,WojdylaD,etal.Preventionofstrokeandsystemicembolismwithrivaroxabancomparedwithwarfarininpatientswith
non-valvularatrialbrillationandmoderaterenalimpairment.EurHeartJ.2011;32:2387‚Äì2394.719.HijaziZ,HohnloserSH,OldgrenJ,etal.Efcacyandsafetyofdabigatrancomparedwithwarfarininpatientswithatrialbrillationinrelationtorenalfunctionovertime‚ÄîaRE-LYtrialanalysis.AmHeartJ.2018;198:169‚Äì177.720.HoriM,MatsumotoM,TanahashiN,etal.SafetyandefcacyofadjusteddoseofrivaroxabaninJapanesepatientswithnon-valvularatrial
brillation:subanalysisofJ-ROCKETAFforpatientswithmoderaterenalimpairment.CircJ.2013;77:632‚Äì638.721.StaniferJ,PokorneyS,ChertowG,etal.Apixabanversuswarfarinin
patientswithatrialbrillationandadvancedchronickidneydisease.Circulation.2020;141:1384‚Äì1392.722.HijaziZ,AlexanderJH,LiZ,etal.ApixabanorvitaminKantagonistsandaspirinorplaceboaccordingtokidneyfunctioninpatientswithatrialb

---

### Chunk 30/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.503

anahashiN,etal.SafetyandefcacyofadjusteddoseofrivaroxabaninJapanesepatientswithnon-valvularatrialbrillation:subanalysisofJ-ROCKETAFforpatientswithmoderaterenalimpairment.CircJ.2013;77:632‚Äì638720;StaniferJ,PokorneyS,ChertowG,etal.Apixabanversuswarfarininpatientswithatrialbrillationandadvancedchronickidneydisease.Circulation.2020;141:1384‚Äì1392721;HijaziZ,AlexanderJH,LiZ,etal.ApixabanorvitaminKantagonistsandaspirinorplaceboaccordingtokidneyfunctioninpatientswithatrialbrillationafteracutecoronarysyndromeorpercutaneouscoronaryinterventioninsightsfromtheAUGUSTUStrial.Circulation.2021;143:1215‚Äì1223.722CI,condenceinterval;CrCl,creatinineclearance;eGFR,estimatedglomerularltrationrate.

---

